Enanta Pharmaceuticals Inc (ENTA) Reports Fiscal Q1 2024 Results: Royalty Revenue Declines Amid ... [Yahoo! Finance]
Enanta Pharmaceuticals, Inc. (ENTA)
Last enanta pharmaceuticals, inc. earnings: 2/6 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.enanta.com/investor-overview
Company Research
Source: Yahoo! Finance
Net Loss : Net loss widened to $33.4 million, or $1.58 per diluted share, compared to a net loss of $29.0 million, or $1.39 per diluted share in the prior year. R&D Expenses : Research and development expenses decreased to $36.4 million from $40.9 million year-over-year. G&A Expenses : General and administrative expenses increased to $16.5 million, up from $12.7 million in the same period last year. Cash Position : Cash and marketable securities totaled $337.2 million, with sufficient funding projected through fiscal year 2027. Pipeline Update : Progress in RSV Phase 2 studies and expansion into immunology with a new KIT inhibitor program. Warning! GuruFocus has detected 4 Warning Signs with ENTA. On February 7, 2024, Enanta Pharmaceuticals Inc ( NASDAQ:ENTA ) released its 8-K filing , detailing the financial results for its fiscal first quarter ended December 31, 2023. The company, known for its innovative approach to developing molecule drugs for viral infections and li
Show less
Read more
Impact Snapshot
Event Time:
ENTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENTA alerts
High impacting Enanta Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ENTA
News
- Strong week for Enanta Pharmaceuticals (NASDAQ:ENTA) shareholders doesn't alleviate pain of five-year loss [Yahoo! Finance]Yahoo! Finance
- Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer [Yahoo! Finance]Yahoo! Finance
- Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal OfficerBusiness Wire
- Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024 [Yahoo! Finance]Yahoo! Finance
ENTA
Earnings
- 2/7/24 - Miss
ENTA
Analyst Actions
- 2/8/24 - JP Morgan
ENTA
Sec Filings
- 5/1/24 - Form 4
- 5/1/24 - Form 3
- 3/12/24 - Form 8-K
- ENTA's page on the SEC website